In May 2012 a collection of five strains of Haemophilus spp was sent to 28 participating reference laboratories in the IBD-labnet surveillance network for quality assurance testing. The laboratories were asked to characterise the five strains by performing standard laboratory protocols for the methods usually used by the laboratory for: species identification, biotyping and serotyping by serological methods and/or PCR.
The results of this EQA are published in the this report.
A double-blind, placebo-controlled, dose-escalation, phase 1 study was performed in 60 healthy subjects between 18 and 49 years of age. The two-dose regimen induced the development of neutralizing antibodies in high percentages of the subjects (from 88% to 100% of subjects depending on antigen content)”.